Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$56.29 USD

56.29
64,081

-0.04 (-0.07%)

Updated Aug 30, 2024 10:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry

by Zacks Equity Research

Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.

Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

by Zacks Equity Research

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

Christopher Vargas headshot

Walgreens (WBA) Becomes Latest Retailer to Suspend Zantac Sales

by Christopher Vargas

Walgreens (WBA) announced today that they would be suspending the sales of Sanofi's (SNY) heartburn medication Zantac.

Zacks.com featured highlights include: Sanofi, KB Home and NRG Energy

by Zacks Equity Research

Zacks.com featured highlights include: Sanofi, KB Home and NRG Energy

Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study

by Zacks Equity Research

Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.

SNY or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SNY vs. NVO: Which Stock Is the Better Value Option?

Swayta Shah headshot

Buy These 3 Stocks With Upgraded Broker Ratings Right Now

by Swayta Shah

After thorough research, brokers decide to rate a particular company's stock. Hence, one can be easily rely on the rating.

Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late

by Zacks Equity Research

Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Here's Why AstraZeneca (AZN) is Outperforming Its Industry

by Zacks Equity Research

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Protalix Completes Enrollment in Third Fabry Disease Study

by Zacks Equity Research

Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.

Moving Average Crossover Alert: Sanofi

by Zacks Equity Research

Sanofi (SNY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Are Investors Undervaluing Sanofi (SNY) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet

by Zacks Equity Research

The CHMP recommends AstraZeneca's (AZN) marketing application for Qtrilmet, a combination of Forxiga and Onglyza plus metformin, for treating patients with type-II diabetes.

Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent

by Zacks Equity Research

Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.

Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Trovagene's Onvansertib Shows Response in Phase Ib AML Study

by Zacks Equity Research

Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.

Urmimala Biswas headshot

CGM Devices Gain Steam, Set New Trend in Diabetes Management

by Urmimala Biswas

The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.

Alnylam Focuses on Pipeline Development Amid Competition

by Zacks Equity Research

Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.

Alnylam Begins Phase III Study on Onpattro for New Indication

by Zacks Equity Research

Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.

    Abbott Partners With Sanofi to Upgrade Diabetes Management

    by Zacks Equity Research

    Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.

    Aimmune's Peanut Allergy Drug Gets FDA Committee's Support

    by Zacks Equity Research

    Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.

    Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use

    by Zacks Equity Research

    Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.

    J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients

    by Zacks Equity Research

    J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.

    Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally

    by Zacks Equity Research

    Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.

    Should Value Investors Buy Sanofi (SNY) Stock?

    by Zacks Equity Research

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.